NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed againstbluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ:BLUE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether bluebird and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until May 28, 2024, to ask the Court to appoint you as Lead Plaintiff for the class if you are a shareholder who purchased or otherwise acquired bluebird securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On December 8, 2023, bluebird announced that the United States Food and Drug Administration approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events. However, the Lyfgenia approval came with a black box warning for haematological malignancies after two patients developed acute myeloid leukemia during the clinical trials. Analysts noted that they did not expect the black box warning or the absence of a priority review voucher.
On this news, bluebird's stock price fell $1.95 per share, or 40.54%, to close at $2.86 per share on December 8, 2023.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Pomerantz LLP
View the original
press release on accesswire.com
